Skip to ContentSkip to Navigation
How to find us dr. M. (Marit) Westerterp
University Medical Center Groningen

dr. M. Westerterp

Associate Professor, Principal Investigator
dr. M. Westerterp
E-mail:
m.westerterp umcg.nl

Postions and Education

Dec 2015 - current     Associate Professor, Dept of Pediatrics

Dec 2015 - current     Adjunct Associate Research Scientist, Dept of Medicine, Columbia University, New York NY

July 2012 - Dec 2015  Associate Research Scientist, Dept of Medicine, Columbia University, New York NY

July 2011 - June 2014 Postdoc, Dept of Medical Biochemistry, Academic Medical Center, University of Amsterdam

July 2007 - June 2012 Postdoc, Dept of Medicine, Columbia University, New York NY

Feb 2003 - June 2007  PhD 'Hyperlipidemia, Inflammation, and Atherosclerosis, roles of apoCI and CETP', Leiden University Medical Center (defense date 12-07-2007)

Oct 2002 - Jan 2003    traineeship, Hoffmann-la Roche, Basel, Switzerland

Sept 1997 - Feb 2003  BSc and MSc Biopharmaceutical Sciences, Leiden University (graduation 11-02-2003)

Funding

2015 - current      Rosalind Franklin Fellowship, UMCG, VIDI and Aspasia grants, NWO

2011 - 2014          VENI grant, NWO

2009 - 2011          Postdoctoral Fellowship, American Heart Association

2007-2009            Rubicon grant NWO

Awards

2017          Steinberg Early Career Award, Arteriosclerosis, Thrombosis, and Vascular Biology

2015          Roger Davis Award, Kern Lipid Conference, Vail CO

2014          Travel Award for Kern Lipid Conference, Vail CO

2014          Travel Award for the Arteriosclerosis, Thrombosis, and Vascular Biology Conference, Toronto ON

2014          Poster Award, Deuel Conference on Lipids, Coronado CA

2006          Poster Award, Gordon Research Conference on Lipoprotein Metabolism, South Hadley MA

2005          Poster Award, Gordon Research Conference on Atherosclerosis, Biddeford ME

2004          Poster Award, Gordon Research Conference on Lipoprotein Metabolism, Meriden NH

2003          Young Investigator Award for Best Oral Presentation, 9th Annual Scandinavian Atherosclerosis Conference (SSAR), Humlebaek, Denmark

Other Experience and Professional Memberships

2011-current   Member American Heart Association, ATVB Council

2014-current   Editorial Board Circulation Research; Gold Reviewer 2014, Platinum Reviewer 2015

Publications

  1. Cochran BJ, Hou L, Manavalan AP, Moore BM, Tabet F, Sultana A, Cuesta Torres L, Tang S, Shrestha S, Senanayake P, Patel M, Ryder WJ, Bongers A, Maraninchi M, Wasinger VC, Westerterp M, Tall AR, Barter PJ, Rye KA. Impact of Perturbed Pancreatic β-cell cholesterol homeostasis on Adipose Tissue and Skeletal Muscle Metabolism. Diabetes 2016;65:3610-20.
  2. Hsieh J, Koseki M, Molusky MM, Yakushiji E, Ichi I, Westerterp M, Iqbal J, Chan RB, Abramowicz S, Tascau L, Takiguchi S, Yamashita S, Welch CL, Di Paolo G, Hussain MM, Lefkowitch JH, Rader DJ, Tall TTC39B deficiency stabilizes LXR reducing both atherosclerosis and steatohepatitis. Nature 2016:535:303-7.
  3. Westerterp M, Wang N, Tall High-Density Lipoproteins, Endothelial Function, and Mendelian Randomization. Circ Res 2016;119:13-5. Editorial.
  4. Westerterp M, Tsuchiya K, Tattersall IW, Fotakis P, Bochem AE, Molusky MM, Ntonga V, Abramowicz S, Parks JS, Welch CL, Kitajewski J, Accili D, Tall Deficiency of ATP-Binding Cassette Transporters A1 and G1 in Endothelial Cells Accelerates Atherosclerosis in Mice. Arterioscler Thromb Vasc Biol 2016:35:1328-37
  5. Zimmer S, Grebe A, Bakke SS, Bode N, Halvorsen B, Ulas T, Skjelland M, De Nardo D, Labzin LI, Kerksiek A, Hempel C, Heneka MT, Hawxhurst V, Fitzgerald ML, Trebicka J, Björkhem I, Gustafsson JÅ, Westerterp M, Tall AR, Wright SD, Espevik T, Schultze JL, Nickenig G, Lütjohann D, Latz E: Cyclodextrin promotes atherosclerosis regression via macrophage reprogramming. Sci Transl Med 2016:333ra50.
  6. Sarrazy V, Viaud M, Westerterp M, Ivanov S, Giorgetti-Peraldi S, Guinamard R, Gautier EL, Thorp EB, De Vivo DC, Yvan-Charvet L: Disruption of Glut1 in Haematopoietic Stem Cells Prevents Myelopoiesis and Enhanced Glucose Flux in Atheromatous Plaques of ApoE(-/-) Mice. Circ Res 2016:118:1062-77.
  7. Sarrazy V, Sore S, Viaud M, Rignol G, Westerterp M, Ceppo F, Tanti JF, Guinamard R, Gautier EL, Yvan-Charvet L: Maintenance of Macrophage Redox Status by ChREBP Limits Inflammation and Apoptosis and Protects against Advanced Atherosclerotic Lesion Formation. Cell Rep 2015:13:132-44.
  8. Bochem AE, Van der Valk FM, Tolani S, Stroes ES, Tall AR*, Westerterp M*. Increased systemic and plaque inflammation in ABCA1 mutation carriers with attenuation by statins. Arterioscler Thromb Vasc Biol 2015:35:1663-9. (*equal co-authorship) Editorial: Bi X, Vitali C, Cuchel M: ABCA1 and Inflammation: From Animal Models to Humans. Arterioscler Thromb Vasc Biol  2015:35:1551-3.
  9. Westerterp M, Tall AR. SORTILIN: Many headed hydra. Circ Res 2015:116:764-6. Editorial.
  10. Jiang H, Westerterp M, Wang C, Zhu Y, Ai D: Macrophage mTORC1 disruption reduces inflammation and insulin resistance in obese mice. Diabetologia 2014:57:2393-404.
  11. Zelcer N, Westerterp M: Adeno-associated viruses as a method to induce atherosclerosis in mice and hamsters. Circ Res 2014;114:1672-4. Editorial.
  12. Ai D, Jiang H, Westerterp M, Murphy AJ, Wang M, Ganda A, Abramowicz S, Welch CL, Almazan F, Zhu Y, Miller YI, Tall AR. Disruption of mTORC1 in Macrophages Decreases Chemokine Gene Expression and Atherosclerosis. Circ Res 2014:114:1576-84.
  13. Wang M, Subramanian M, Abramowicz S, Murphy AJ, Gonen A, Witztum J, Welch C, Tabas I, Westerterp M, Tall AR: Interleukin-3/Granulocyte Macrophage Colony-Stimulating Factor Receptor Promotes Stem Cell Expansion, Monocytosis, and Atheroma Macrophage Burden in Mice With Hematopoietic ApoE Deficiency. Arterioscler Thromb Vasc Biol 2014:34:976-84.
  14. Murphy AJ, Sarrazy V, Wang N, Bijl N, Abramowicz S, Westerterp M, Welch CB, Schuetz JD, Yvan-Charvet L: Deficiency of ATP-Binding Cassette Transporter B6 in Megakaryocyte Progenitors Accelerates Atherosclerosis in Mice. Arterioscler Thromb Vasc Biol 2014;34:751-8.
  15. Westerterp M, Bochem AE, Yvan-Charvet L, Murphy AJ, Wang N, Tall AR: ABC Transporters, Atherosclerosis, Inflammation. Circ Res 2014:114:157-70. Review.
  16. Kappus MS, Murphy AJ, Abramowicz S, Ntonga V, Welch CL, Tall AR, Westerterp M: Activation of Liver X Receptor Decreases Atherosclerosis in Ldlr-/- Mice in the Absence of ABCA1 and ABCG1 in Myeloid Cells. Arterioscler Thromb Vasc Biol 2014:34:279-284. Editorial: Ignatova ID, Schulman IG: Liver X Receptors and Atherosclerosis – It Is Not All Cholesterol. Arterioscler Thromb Vasc Biol 2014:34:242-243.
  17. Nagareddy PR, Murphy AJ, Stirzaker RA, Hu Y, Yu S, Miller RG, Ramkhelawon B, Distel E, Westerterp M, Huang LS, Schmidt AM, Orchard TJ, Fisher EA, Tall AR, Goldberg IJ: Hyperglycemia promotes myelopoiesis and impairs the resolution of atherosclerosis. Cell Metab 2013:17:695-708. Editorial: Brownlee M: Hyperglycemia-stimulated myelopoiesis caused impaired regression of atherosclerosis in type 1 diabetes. Cell Metab 2013:17:631-3.
  18. Westerterp M, Murphy AJ, Wang M, Pagler TA, Vengrenyuk Y, Kappus MS, Gorman DJ, Nagareddy PR, Zhu X, Abramowicz S, Parks JS, Welch C, Fisher EA, Wang N, Yvan-Charvet L, Tall AR: Deficiency of ATP-binding cassette transporters A1 and G1 in macrophages increases inflammation and accelerates atherosclerosis mice. Circ Res 2013:112:1456-65. Issue highlight.
  19. Garcia-Arcos I, Hiyama Y, Drosatos K, Bharadwaj KG, Hu Y, Son NH, O'Byrne SM, Chang CL, Deckelbaum RJ, Takahashi M, Westerterp M, Obunike JC, Jiang H, Yagyu H, Blaner WS, Goldberg IJ: Adipose-specific lipoprotein lipase deficiency more profoundly affects brown than white fat biology. J Biol Chem 2013:288:14046-58.
  20. Martel C, Li W, Fulp B, Platt AM, Gautier EL, Westerterp M, Bittman R, Tall AR, Chen SH, Thomas MJ, Kreisel D, Swartz MA, Sorci-Thomas MG, Randolph GJ: Lymphatic vasculature mediates macrophage reverse cholesterol transport in mice. J Clin Invest 2013:123:1571-9. Editorial: Fernández-Hernando C: Lymphatic vessels clean up your arteries. J Clin Invest 2013:123:1417-9.
  21. Tsuchiya K, Westerterp M, Murphy AJ, Subramanian V, Ferrante AW Jr, Tall AR, Accili D: Expanded granulocyte/monocyte compartment in myeloid-specific triple FoxO knockout increases oxidative stress and accelerates atherosclerosis in mice. Circ Res 2013:112(7):992-1003. Editorial: Feinberg MW: OutFOXing myeloid cells in atherosclerosis with FoxOs. Circ Res 2013:112:978-82.
  22. Gautier EL, Westerterp M, Bhagwat N, Cremers S, Shih A, Abdel-Wahab O, Lütjohann D, Randolph GJ, Levine RL, Tall AR, Yvan-Charvet L: HDL and Glut1 inhibition reverse a hypermetabolic state in mouse models of myeloproliferative disorders. J Exp Med 2013:210:339-53.
  23. Tall AR, Yvan-Charvet L, Westerterp M, Murphy AJ: Cholesterol efflux: a novel regulator of myelopoiesis and atherogenesis. Arterioscler Thromb Vasc Biol 2012:32:2547-52.
  24. Westerterp M*, Gourion-Arsiquaud S*, Murphy AJ*, Shih A, Cremers S, Levine RL, Tall AR, Yvan-Charvet L: Regulation of hematopoietic stem and progenitor cell mobilization by cholesterol efflux pathways. Cell Stem Cell 2012:11:195-206. With Editorial: Suratt BT, Fessler MB: Greasing the way: the ABCs of HSPC efflux from the marrow. Cell Stem Cell 2012:11:143-4. (*equal co-authorship)
  25. Murphy AJ, Westerterp M, Yvan-Charvet L, Tall AR: Anti-atherogenic mechanisms of high density lipoprotein: effects on myeloid cells. Biochim Biophys Acta 2012:1821:513-21.
  26. Pagler TA, Wang M, Mondal M, Murphy AJ, Westerterp M, Moore KJ, Maxfield FR, Tall AR: Deletion of ABCA1 and ABCG1 impairs macrophage migration because of increased Rac1 signaling. Circ Res 2011: 108:194-200.
  27. Westerterp M*, Terasaka N*, Koetsveld J, Fernández-Hernando C, Yvan-Charvet L, Wang N, Sessa WC, Tall AR: ABCG1 and HDL promote endothelial NO synthesis through a decrease in the interaction of caveolin-1 and endothelial NO synthase. Arterioscler Thromb Vasc Biol 2010:30:2219-2225. (*equal co-authorship)
  28. Westerterp M, Koetsveld J, Yu S, Han S, Li R, Goldberg IJ, Welch CL, Tall AR: Increased atherosclerosis in mice with vascular ATP-Binding Cassette Transporter G1 deficiency. Arterioscler Thromb Vasc Biol 2010:30:2103-2105.
  29. Ishibashi M, Masson D, Westerterp M, Wang N, Sayers S, Li R, Welch CL, Tall AR: Reduced VLDL clearance in Apoe(-/-)Npc1(-/-) mice is associated with increased Pcsk9 and Idol expression and decreased hepatic LDL-receptor levels. J Lipid Res 2010:51:2655-63.
  30. Westerterp M, Koetsveld J, Tall AR: Cholesteryl ester transfer protein inhibition: a dysfunctional endothelium? J Cardiovasc Pharmacol 2010:55:456-8.
  31. Berbée JF, Coomans CP, Westerterp M, Romijn JA, Havekes LM, Rensen PC: Apolipoprotein CI enhances the biological response to LPS via the CD14/TLR4 pathway by LPS-binding elements in both its N- and C-terminal helix. J Lipid Res 2010:51:1943-52.
  32. den Boer MA, Westerterp M, de Vries-van der Weij J, Wang Y, Hu L, Espirito Santo SM, Kooistra T, Reiss P, Romijn JA, Havekes LM, Rensen PC: Ritonavir protects against the development of atherosclerosis in APOE*3-Leiden mice. Atherosclerosis 2010:210:381-7.
  33. Han S, Liang CP, Westerterp M, Sennokuchi T, Welch CL, Wang Q, Matsumoto M, Accili D, Tall AR: Hepatic insulin signalling regulates VLDL secretion and atherogenesis in mice. J Clin Invest 2009:119:1029-41.
  34. de Haan W, de Vries-van der Weij J, van der Hoorn JW, Gautier T, van der Hoogt CC, Westerterp M, Romijn JA, Jukema JW, Havekes LM, Princen HM, Rensen PC: Torcetrapib does not reduce atherosclerosis beyond atorvastatin and induces more proinflammatory lesions than atorvastatin. Circulation 2008:117:2515-22.
  35. Westerterp M, Berbée JFP, Pires NMM, Van Mierlo GJD, Kleemann R, Romijn JA, Havekes LM, Rensen PC: Apolipoprotein CI is Crucially Involved in Lipopolysaccharide-Induced Atherosclerosis in ApoE-Knockout Mice. Circulation 2007:116:2173-81.
  36. de Haan W, van der Hoogt CC, Westerterp M, Hoekstra M, Dallinga-Thie GM, Princen HM, Romijn JA, Jukema JW, Havekes LM, Rensen PC: Atorvastatin Increases HDL cholesterol by Reducing CETP expression in cholesterol-fed APOE*3-Leiden.CETP Atherosclerosis 2008:197:57-63.
  37. van der Hoogt CC, de Haan W, Westerterp M, Hoekstra M, Dallinga-Thie GM, Romijn JA, Princen HM, Jukema JW, Havekes LM, Rensen PC: Fenofibrate increases HDL-cholesterol by reducing cholesteryl ester transfer protein expression. J Lipid Res 2007:48:1763-71.
  38. Westerterp M, Berbée JF, Delsing DJ, Jong MC, Gijbels MJ, Dahlmans VE, Offerman EH, Romijn JA, Havekes LM, Rensen PC: Apolipoprotein C-I binds free fatty acids and reduces their intracellular esterification. J Lipid Res 2007:48:1353-61.
  39. Westerterp M, Van Eck M, de Haan W, Offerman EH, Van Berkel TJ, Havekes LM, Rensen PC: Apolipoprotein CI aggravates atherosclerosis development in ApoE-knockout mice despite mediating cholesterol efflux from macrophages. Atherosclerosis 2007:195:e9-16.
  40. Westerterp M, Van der Hoogt CC, De Haan W, Offerman EH, Dallinga-Thie GM, Jukema JW, Havekes LM, Rensen PC: Cholesteryl ester transfer protein expression decreases HDL and severely aggravates atherosclerosis in APOE*3-Leiden Arterioscler Thromb Vasc Biol 2006:26:2552-59.
  41. Westerterp M, de Haan W, Berbée JF, Havekes LM, Rensen PC: Endogenous apoC-I increases hyperlipidemia in apoE-knockout mice by stimulating VLDL production and inhibiting LPL. J Lipid Res 2006:47:1203-11.

 

                       

Last modified:21 February 2017 3.18 p.m.

Contact information

Antonius Deusinglaan 1
9713 AV Groningen
The Netherlands

ERIBA Building, Antonius Deusinglaan 1, 9713 AV Groningen

Phone number: